Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EPS (Basic): 2009-2024

Historic EPS (Basic) for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $0.16.

  • Tg Therapeutics' EPS (Basic) rose 8866.67% to $2.69 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.07, marking a year-over-year increase of 3511.11%. This contributed to the annual value of $0.16 for FY2024, which is 77.78% up from last year.
  • According to the latest figures from FY2024, Tg Therapeutics' EPS (Basic) is $0.16, which was up 77.78% from $0.09 recorded in FY2023.
  • Tg Therapeutics' 5-year EPS (Basic) high stood at $0.16 for FY2024, and its period low was -$2.63 during FY2021.
  • Moreover, its 3-year median value for EPS (Basic) was $0.09 (2023), whereas its average is -$0.47.
  • Its EPS (Basic) has fluctuated over the past 5 years, first decreased by 23.47% in 2020, then skyrocketed by 105.45% in 2023.
  • Yearly analysis of 5 years shows Tg Therapeutics' EPS (Basic) stood at -$2.42 in 2020, then fell by 8.68% to -$2.63 in 2021, then skyrocketed by 37.26% to -$1.65 in 2022, then surged by 105.45% to $0.09 in 2023, then soared by 77.78% to $0.16 in 2024.